J Breast Cancer.  2009 Dec;12(4):278-284. 10.4048/jbc.2009.12.4.278.

Phase II Study of Vinorelbine Plus Ifosfamide in Patients with Taxane-resistant Metastatic Breast Cancer

• Lee S
• Oh SY
• Kwon HC
• Kim SH
• Kwon KA
• Hsing CT
• Kim DC
• Lee JH
• Lee HS
• Lee MR
• Cho SH
• Kim HJ

• KMID: 2175521
• DOI: http://doi.org/10.4048/jbc.2009.12.4.278

Abstract

PURPOSE
The patients with metastatic breast cancer are routinely exposed to taxane and anthracycline as neoadjuvant, adjuvant, and palliative chemotherapeutic agents. This study was designed to evaluate the efficacy and safety of using a vinorelbine and ifosfamide (VI) combination treatment in patients with taxane-resistant metastatic breast cancer. METHODS: We evaluated the use of a VI regimen (25 mg/m2 vinorelbine administered on days 1 and 8 plus 2,000 mg/m2 ifosfamide administered on day 1-3 every 3 weeks) for breast cancer patients who evidenced tumor progression after palliative taxane treatment. RESULTS: Overall, 35 patients were enrolled in this study: Their median age was 50 years (range, 38-72 years). The overall response rate was 40.0% (14 patients; 95% confidence interval [CI], 23-57%). The median time to progression was 4.5 months (95% CI, 3.5-5.4 months). The median overall survival was 18.3 months (95% CI, 12.9-23.6 months). In the 190 cycle of treatment, the incidence of grade > or =3 neutropenia, anemia, and thrombocytopenia was 29.3%, 4.2%, and 2.0%, respectively. Neutropenic fever was noted in 6 cycles (3.1%). The non-hematological toxicities were not severe: grade 1 or 2 vomiting was observed in 22.8% of the patients. CONCLUSION: Our results suggest that the use of vinorelbine and ifosfamide (VI) combination chemotherapy appears to be effective and it showed an acceptable toxicity profile in the patients with taxane-resistant metastatic breast cancer.

Keyword

Breast neoplasms; Ifosfamide; Taxane; Vinorelbine

MeSH Terms

Anemia
Breast
Breast Neoplasms
Bridged Compounds
Drug Therapy, Combination
Fever
Humans
Ifosfamide
Incidence
Neutropenia
Taxoids
Thrombocytopenia
Vinblastine
Vomiting
Bridged Compounds
Ifosfamide
Taxoids
Vinblastine

Figure

• 

  Figure 1 A demonstration of the time to progression of the patients. The median time to progression was 4.5 months (95/% CI, 3.5-5.4 months).

• 

  Figure 2 The overall survival of patients. The median overall survival was 18.3 months (95% CI, 12.9-23.6 months).

Reference

1. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998. 339:974–984.

2. Krikorian A, Rahmani R, Bromet M, Bore P, Cano JP. Pharmacokinetics and metabolism of Navelbine. Semin Oncol. 1989. 16:21–25.

3. Hortobagyi GN. Future directions for vinorelbine (Navelbine). Semin Oncol. 1995. 22:80–86.

4. Fumoleau P, Delozier T, Extra JM, Canobbio L, Delgado FM, Hurteloup P. Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience. Semin Oncol. 1995. 22:22–28.

5. Canobbio L, Boccardo F, Pastorino G, Brema F, Martini C, Resasco M, et al. Phase-II study of Navelbine in advanced breast cancer. Semin Oncol. 1989. 16:33–36.

6. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol. 1994. 12:2094–2101.

7. Mano M. Vinorelbine in the management of breast cancer: new perspectives, revived role in the era of targeted therapy. Cancer Treat Rev. 2006. 32:106–118.

8. Sorio R, Lombardi D, Spazzapan S, La Mura N, Tabaro G, Veronesi A. Ifosfamide in advanced/disseminated breast cancer. Oncology. 2003. 65:55–58.

9. Overmoyer BA. Ifosfamide in the treatment of breast cancer. Semin Oncol. 1996. 23:38–41.

10. Brade WP, Herdrich K, Varini M. Ifosfamide--pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985. 12:1–47.

11. Goldin A. Ifosfamide in experimental tumor systems. Semin Oncol. 1982. 9:14–23.

12. Buzdar AU, Legha SS, Tashima CK, Yap HY, Hortobagyi GN, Hersh EM, et al. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep. 1979. 63:115–120.

13. Bitran JD, Samuels BL, Marsik S, Gambino A, White L. A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer. Clin Cancer Res. 1995. 1:185–188.

14. Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E, et al. A Phase I trial of ifosfamide and paclitaxel with granulocytecolony stimulating factor in the treatment of patients with refractory solid tumors. Cancer. 1998. 82:561–566.

15. Kosmas C, Tsavaris N, Malamos N, Stavroyianni N, Gregoriou A, Rokana S, et al. Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. Br J Cancer. 2003. 88:1168–1174.

16. Kosmas C, Tsavaris N, Malamos N, Tsakonas G, Gassiamis A, Polyzos A, et al. Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines. Invest New Drugs. 2007. 25:463–470.

17. Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer. 2000. 82:529–534.

18. Leone BA, Vallejo CT, Romero AO, Perez JE, Cuevas MA, Lacava JA, et al. Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol. 1996. 14:2993–2999.

19. Pronzato P, Queirolo P, Landucci M, Vaira F, Vigani A, Gipponi M, et al. Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. Breast Cancer Res Treat. 1997. 42:183–186.

20. Aziz Z, Rehman A, Qazi S. Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy. Cancer Chemother Pharmacol. 1999. 44:S9–S12.

21. Campisi C, Fabi A, Papaldo P, Tomao S, Massidda B, Zappala A, et al. Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. Ann Oncol. 1998. 9:565–567.

22. Lobo F, Frau A, Barnadas A, Mendez M, Lizon J, Provencio M, et al. Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. Cancer Chemother Pharmacol. 1999. 44:S5–S8.

23. Overmoyer B. Options for the treatment of patients with taxane-refractory metastatic breast cancer. Clin Breast Cancer. 2008. 8:S61–S70.

24. Penninx BW, Pahor M, Cesari M, Corsi AM, Woodman RC, Bandinelli S, et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc. 2004. 52:719–724.

25. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY, et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983. 1:776–786.